Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases

Pharmacogenomics Journal

Volumn 14, Issue 4, 2014, Pages 356-364

  Cobb, J ^a,b   Cule, E ^c   Moncrieffe, H ^d   Hinks, A ^a   Ursu, S ^d   Patrick, F ^d   Kassoumeri, L ^d   Flynn, E ^a   Bulatovic M ^e   Wulffraat, N ^e   Van Zelst, B ^f   De Jonge, R ^f   Bohm, M ^g   Dolezalova, P ^g   Hirani, S ^h   Newman, S ^h   Whitworth, P ⁱ   Southwood, T R ⁱ   De Iorio, M ^j   Wedderburn, L R ^d   Thomson, W ^a,b   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g CHARLES UNIVERSITY   (Czech Republic)

^h CITY UNIVERSITY   (United Kingdom)

ⁱ BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

juvenile idiopathic arthritis; methotrexate; pharmacogenetics; response

Indexed keywords

METHOTREXATE;

ARTICLE; CFTR GENE; CHILD; CLINICAL ASSESSMENT; COHORT ANALYSIS; CZECH REPUBLIC; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOME; GENOTYPE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TGIF1 GENE; TREATMENT RESPONSE; UNITED KINGDOM; VISUAL ANALOG SCALE; ZMIZ1 GENE; ARTHRITIS, JUVENILE; GENETICS; PRESCHOOL CHILD;

ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; MALE; METHOTREXATE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84923856898     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.3     Document Type: Article

References (47)

1. Moorthy LN, Peterson MG, Hassett AL, Lehman TJ. Burden of childhood-onset arthritis. Pediatr Rheumatol Online J 2010; 8: 20.
2. De K, I, Brinkman DM, Ferster A, Abinun M, Quartier P, Van Der NJ et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis 2004; 63: 1318-1326.
3. Magni-Manzoni S, Rossi F, Pistorio A, Temporini F, Viola S, Beluffi G et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum 2003; 48: 3509-3517.
4. Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 2809-2818.
5. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012; 64: 2012-2021.
6. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-2201.
7. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63: 929-936.
8. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011; 63: 437-459.
9. Bulatovic M, Heijstek MW, Van Dijkhuizen EH, Wulffraat NM, Pluijm SM, de JR. Prediction of clinical non-response to methotrexate treatment in juvenile idio-pathic arthritis. Ann Rheum Dis 2012; 71: 1484-1489.
10. de Rotte MC, Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RH et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol 2012; 39: 2032-2040.
11. Dervieux T, Wessels JA, Kremer JM, Padyukov L, Seddighzadeh M, Saevarsdottir S et al. Patterns of interaction between genetic and nongenetic attributes and metho-trexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics 2012; 22: 1-9.
12. Hinks A, Moncrieffe H, Martin P, Ursu S, Lal S, Kassoumeri L et al. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis 2011; 70: 1395-1400.
13. Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford) 2009; 48: 613-617.
14. Moncrieffe H, Hinks A, Ursu S, Kassoumeri L, Etheridge A, Hubank M et al. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenet Genomics 2010; 20: 665-676.
15. Schmeling H, Biber D, Heins S, Horneff G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 1832-1836.
16. Wessels JA, van der Kooij SM, le CS, Kievit W, Barerra P, Allaart CF et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007; 56: 1765-1775.
17. Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics 2013; 14: 305-314.
18. Wang J, Bansal AT, Martin M, Germer S, Benayed R, Essioux L et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J 2013; 13: 235-241.
19. Adib N, Hyrich K, Thornton J, Lunt M, Davidson J, Gardner-Medwin J et al. Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 2008; 47: 991-995.
20. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-392.
21. Nugent J, Ruperto N, Grainger J, Machado C, Sawhney S, Baildam E et al. The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19(4 Suppl 23): S163-S167.
22. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-1209.
23. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006; 2: e190.
24. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
25. Price AL, Weale ME, Patterson N, Myers SR, Need AC, Shianna KV et al. Long-range LD can confound genome scans in admixed populations. Am J Hum Genet 2008; 83: 132-135.
26. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
27. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336-2337.
28. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods 2012; 9: 179-181.
29. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529.
30. Martin P, Barton A, Eyre S. ASSIMILATOR: a new tool to inform selection of associated genetic variants for functional studies. Bioinformatics 2011; 27: 144-146.
31. Ellis JA, Munro JE, Chavez RA, Gordon L, Joo JE, Akikusa JD et al. Genome-scale case-control analysis of CD4 + T-cell DNA methylation in juvenile idiopathic arthritis reveals potential targets involved in disease. Clin Epigenetics 2012; 4: 20.
32. Veyrieras JB, Kudaravalli S, Kim SY, Dermitzakis ET, Gilad Y, Stephens M et al. Highresolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genet 2008; 4: e1000214.
33. Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Paediatr Drugs 2011; 13: 161-173.
34. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465-482.
35. Ott CJ, Blackledge NP, Kerschner JL, Leir SH, Crawford GE, Cotton CU et al. Intronic enhancers coordinate epithelial-specific looping of the active CFTR locus. Proc Natl Acad Sci USA 2009; 106: 19934-19939.
36. Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics 2005; 15: 523-533.
37. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012; 90: 636-647.
38. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125.
39. Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009; 41: 1335-1340.
40. Patsopoulos NA, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011; 70: 897-912.
41. Li X, Thyssen G, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity. J Biol Chem 2006; 281: 23748-23756.
42. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317: 256-260.
43. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro-and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford) 2009; 48: 602-606.
44. Pessah M, Prunier C, Marais J, Ferrand N, Mazars A, Lallemand F et al. c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity. Proc Natl Acad Sci USA 2001; 98: 6198-6203.
45. Wolff S, Harper PA, Wong JM, Mostert V, Wang Y, Abel J. Cell-specific regulation of human aryl hydrocarbon receptor expression by transforming growth factor-beta(1). Mol Pharmacol 2001; 59: 716-724.
46. Comabella M, Craig DW, Morcillo-Suarez C, Rio J, Navarro A, Fernandez M et al. Genome-wide scan of 500, 000 single-nucleotide polymorphisms among respon-ders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66: 972-978.
47. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010; 11: 241-246.